- by tjasa
- February 21, 2023
The production of viral vectors for gene therapy is focused on pure, safe, and efficacious products. Absence of impurities and presence of
full vector genomes play a crucial role. We have addressed the problem of AAV vector genome integrity by developing an advanced dPCR
multiplex approach (NibaPlex®). The newly developed 4-plex assay was qualified on DNA level and tested on several different AAV vectors to show its applicability. The assay is an upgrade from simplex vector genome titering assay by providing accurate quantitative result on genome
integrity. The use of such assay can better guide process development with a goal of having as much full vector genomes as possible.